PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 25, 2016

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Prostate CancerAdvanced Renal Cell CarcinomaAdvanced Urothelial CarcinomaGenitourinary Cancer
Interventions
OTHER

Systemic therapy

Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

DEVICE

StrataNGS

CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Prostate Cancer Foundation

OTHER

collaborator

Strata Oncology

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT02735252 - PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer | Biotech Hunter | Biotech Hunter